VibroSense Dynamics has in recent weeks started a clinical validation at Skåne University Hospital (SUS) of the new application Diabetes Foot Screening, which is the latest innovation in the instrument VibroSense Meter® II. The company follows the plan previously communicated and the clinical validation is the last phase prior to the commercial launch of the product within the Diabetes segment. The launch is expected to start in the later months of 2020. As part of the launch, targeted marketing and communication activities will be performed to approach main target groups in the Diabetes community.

In conjunction with World Diabetes Day on November 14, 2020, VibroSense is increasing its presence in the media with the goal of building awareness in the prioritized target groups: people living with diabetes and care providers within diabetes care.

• This is an important and very exciting step, to be able to meet a great need, in both patients and clinicians working within diabetes. With our new application Diabetes Foot Screening, we offer strong support for early, fast and reliable identification of people at risk of developing foot ulcers as a result of loss of sense in the foot. Our new application Diabetes Foot Screening is intended for both specialist clinics and primary care, says Hans Wallin, CEO VibroSense Dynamics AB.

Contact

Hans Wallin, CEO VibroSense Dynamics AB,
Tel: +46 40 88 026
E-mail: info@vibrosense.com
www.vibrosense.com

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (public) sells and develops efficient systems to support early detection and diagnosis of sensory neuropathy, i.e. disease of large nerve fibres and nerve trunks in e.g. legs and arms. Our vision is that the VibroSense Meter shall be the golden standard instrument for neurological examinations to assess sensory neuropathy and help to improve life conditions for patients having a risk of getting nerve injuries.